BioMarin Pharmaceutical, Inc.
(NASDAQ : BMRN)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -0.32%333.780.0%$4532.00m
NVAXNovavax, Inc. -0.51%165.4079.4%$744.04m
BNTXBioNTech SE 1.71%265.570.0%$716.89m
AMGNAmgen, Inc. 1.16%205.481.4%$544.47m
SNSSSunesis Pharmaceuticals, Inc. 0.64%6.300.7%$440.39m
REGNRegeneron Pharmaceuticals, Inc. 1.96%554.152.7%$427.79m
GILDGilead Sciences, Inc. 1.12%66.641.0%$412.41m
CCXIChemoCentryx, Inc. 5.40%34.182.9%$405.99m
ILMNIllumina, Inc. 0.15%411.133.3%$375.21m
XLRNAcceleron Pharma, Inc. 0.23%173.395.3%$363.27m
VRTXVertex Pharmaceuticals, Inc. 1.98%184.381.9%$263.38m
BIIBBiogen, Inc. 0.40%270.811.7%$234.60m
OCGNOcugen, Inc. 2.00%8.430.0%$182.22m
XENEXenon Pharmaceuticals, Inc. 1.03%31.040.4%$173.54m
CRSPCRISPR Therapeutics AG 4.41%100.450.6%$161.01m

Company Profile

BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997 and is headquartered in San Rafael, CA.